HIMA and Medicare reform
This article was originally published in The Gray Sheet
Health Industry Manufacturers Association position paper advocates a patient-centered approach to provide beneficiaries with greater choice of competing health plans. The Health Care Financing Administration's role in such a system "should be to administer Medicare's fee-for-service system, which should continue to be available to beneficiaries," HIMA maintains. Separately, the association announces the appointment of Blair Childs as executive VP-strategic planning and implementation. Childs, currently president of the Strategic Advisory Group consulting firm, will be responsible for directing efforts in coalition development, grassroots and communications
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.